L-Ornithine L-Aspartate

BACKGROUND / AIMS: In the current knowledge of the pathophysiology of hepatic encephalopathy, a reduction of hyperammonemia is the most important evidence for effective treatment. Therefore, the therapeutic efficacy of oral L-ornithine L-aspartate, ammonia detoxification with improved faculties studied in patients with cirrhosis, hyperammonemia and stable, open chronic hepatic encephalopathy and subclinical hepatic encephalopathy in a randomized , double-blind, placebo-controlled clinical trial.

Methods: Oral L-ornithine L-aspartate was administered three times daily at fixed times for 14 consecutive days in a total dose of 18 g per day. The design has been chosen to increase the ammonia can be induced by a protein powder, 0.25 g / kg body weight administered daily to prevent the start of the treatment period. Efficacy variables were: fasting and postprandial ammonia concentration, number connection test time, mental state and qualities of an index of portosystemic encephalopathy. The analyzes were performed on the total population of the study and placebo 32 34 L-ornithine L-aspartate treated patients and the sub-groups of samples in the open air (20 placebo and 23 L-ornithine L-aspartate treaties) on the base and subclinical hepatic encephalopathy (12 placebo and 11 L-ornithine L-aspartate) treated patients.

Results: connection test performance time at (p <0.01) and fasting (p <0.01) and postprandial (p <0.05) showed venous blood ammonia concentrations in the group L-aspartate-L-ornithine treated an improvement relative to placebo. In addition, the mental state level (p <0.05) and the index of portosystemic encephalopathy (p <0.01) significantly improved in group L-aspartate L-ornithine as in the placebo group. Side effects have been observed in placebo patients or L-aspartate-treated L-ornithine.